Genfit’s programs are coordinated to focus on solutions:

•  In early diagnosis, prevention, and treatment of disorders associated with prediabetes and diabetes, by approaching diabetic pathology from different perspectives,
• In handling Alzheimer’s disease, by capitalizing on the key role of nuclear receptors at the interface between neurodegenerative and metabolic diseases,
• In the field of theranostics, by exploiting a novel cutting-edge technology to develop companion tests that can be integrated into R&D strategies for the assessment of drug candidates.

Learn more on key programs or have a closer look at our most advanced compound in clinical development.   

TARGETING PREDIABETES AND DIABETES

Ranging from risk factors such as lipid disorders and altered glycemia to micro- and macrovascular diseases including atherosclerosis, myocardial infarction, stroke, anddiabetic nephropathy, disorders associated with prediabetes and diabetes represent a major challenge for public health worldwide.

Through complementary approaches covering the diagnosis, prevention and treatment of these disorders, Genfit has developed a rich and diversified program pipeline of potential blockbusters in clinical and preclinical phases, as well as innovative therapeutic targets that will undeniably provide the basis for future first-in-class drugs.

Learn more about Prediabetes and Diabetes.

HANDLING ALZHEIMER'S DISEASE

Neurodegenerative disorders, and particularly Alzheimer’s disease, are a therapeutic  area where there are still major unmet medical needs.

Stemming from its extensive knowledge in metabolic disease and its expertise in nuclear receptor biology, Genfit is focusing on nuclear receptors as key targets that are linked to both metabolic and neurodegenerative disorders, in order to address Alzheimer’s disease.

Learn more about the interlinked biology of neurodegenerative and cardiometabolic diseases.

MOVING FORWARD IN THERANOSTICS

The concerns of the pharmaceutical industry and healthcare authorities are such that it is clearly of great interest to possess tools that enable the rapid and precise assessment of patient responses to new therapeutic treatments. 

Genfit has made major advances in the development of a cutting-edge non-invasive, non-imaging biomarker technology, that should enable a fast, focused and predictive analysis of the effectiveness of new treatments dedicated to certain metabolic and neurodegenerative diseases.